Aligos Therapeutics (ALGS) Other Non-Current Liabilities (2019 - 2024)

Aligos Therapeutics (ALGS) has reported Other Non-Current Liabilities for 6 consecutive years, with $72.4 million the latest figure, recorded in Q4 2024.

• For the quarter ending Q4 2024, Other Non-Current Liabilities rose 162.24% year-over-year to $72.4 million; the trailing twelve-month figure through Dec 2024 stood at $72.4 million (up 162.24% YoY), and the FY2024 full-year result was $72.4 million, up 162.24% from the prior year.
• Other Non-Current Liabilities grew to $72.4 million in Q4 2024 per ALGS's latest filing, from $11.6 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $72.4 million in Q4 2024 and bottomed at $133000.0 in Q4 2021.
• Historically, Other Non-Current Liabilities has averaged $12.0 million across 5 years, with a median of $323000.0 in 2020.
• The sharpest annual moves came in 2021 and 2024: Other Non-Current Liabilities plunged 64.91% in 2021, then surged 162.24% in 2024.
• Over 5 years, Other Non-Current Liabilities stood at $379000.0 in 2020, then slumped by 64.91% to $133000.0 in 2021, then changed by 0.0% to $133000.0 in 2022, then soared by 20648.87% to $27.6 million in 2023, then jumped by 162.24% to $72.4 million in 2024.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $72.4 million, $11.6 million, and $11.5 million for Q4 2024, Q3 2024, and Q2 2024 respectively.